Bristol Myers Squibb: Opdivo-Qvantig is the first FDA approved subcutaneous version of cancer immunotherapy targeting PD-1
Opdivo-Qvantig had a non-inferior objective response rate compared to intravenous formulation in patients with locally advanced or metastatic clear cell...







![Active smoking cessation intervention may provide tangible results [Project CLIQ]](https://www.2minutemedicine.com/wp-content/uploads/2014/12/smoking-e1418644951268-350x250.jpg)


